Core Viewpoint - Extendicare Inc. has received approval from the Toronto Stock Exchange for the renewal of its normal course issuer bid, allowing the company to repurchase up to 7,281,193 common shares, which is 10% of its public float [1][4] Group 1: NCIB Details - The NCIB will commence on July 2, 2025, and will continue until July 1, 2026, or until the bid is completed [2] - Daily purchases under the NCIB will be limited to 44,803 common shares based on the average daily trading volume of 179,213 shares over the last six months [2] - All common shares purchased under the NCIB will be cancelled [3] Group 2: Rationale and Strategy - The board of directors believes that purchasing common shares may be an attractive use of corporate funds based on market conditions and share price [4] - The company has not purchased any shares under its previous NCIB, which allowed for the purchase of up to 7,159,997 common shares [5] Group 3: Automatic Purchase Plan - Extendicare has established an automatic purchase plan with its designated broker to facilitate share purchases during regulatory black-out periods [6] Group 4: Company Overview - Extendicare is a leading provider of care and services for seniors in Canada, operating 99 long-term care homes and delivering approximately 11.2 million hours of home health care services annually [7] - The company employs around 26,500 qualified team members dedicated to providing high-quality care [7]

Core Insights - BrightSpring Health Services, Inc. (BTSG) is experiencing significant growth in its Home Health Care segment, driven by the expanding global home healthcare market, which is projected to grow at a CAGR of 10.21% from 2025 to 2030 [1] Company Performance - The Home Health Care segment generated $178 million in sales in Q1 2025, reflecting a 21% year-over-year increase, supported by strong operational execution and expanding Medicare Advantage contracts [2][8] - The average daily census across home health and hospice increased to over 30,000, a 12% rise from the previous year, indicating robust demand for services [3] - Approximately 90% patient satisfaction was reported, with over 80% of branches rated 4 stars or higher, and a declining 60-day hospitalization rate [2][3] Strategic Initiatives - BrightSpring is advancing its Homebase Primary Care model to provide physician-led services in cost-effective, in-home settings, and is targeting scalable growth to over 100,000 patients through value-based models like ACOs and SNPs [3] Competitive Landscape - Cardinal Health's at-Home Solutions is expanding its reach in the home healthcare market, serving over 5 million patients in fiscal 2024 and investing in automated distribution centers to enhance capabilities [4] - Addus HomeCare Corporation's home healthcare segment is experiencing modest growth, focusing on selective M&A and leveraging technology for operational synergies [5] Market Valuation - BTSG shares have increased by 98.8% over the past year, significantly outperforming the industry, which saw an 18.9% decline, while the S&P 500 composite grew by 11.8% [6] - The company trades at a forward price-to-earnings ratio of 20.32, above the industry average of 14.25 [9] Earnings Estimates - The Zacks Consensus Estimate for BTSG's earnings has been rising over the past 60 days, with current estimates for Q2 2025 at $0.22 and for the current year at $1.02 [10][11]

Core Points - Extendicare Inc. has completed the acquisition of nine "Class C" long-term care homes and a parcel of vacant land from Revera Inc. effective June 1, 2025 [1] - The total consideration for the transaction was approximately $60.3 million, consisting of $40.2 million in cash and the assumption of $20.1 million in liabilities [2] - The acquired homes include a total of 822 long-term care beds and 574 retirement beds across various locations in Ontario and Manitoba [3] Financial Details - The purchase price was funded from cash on hand, excluding transaction costs [2] - The liabilities assumed include government funding reimbursement obligations and committed capital maintenance project obligations [2] Operational Insights - Carlingview Manor is undergoing redevelopment into a new 320-bed long-term care home, owned by a joint venture between Extendicare and Axium [4] - Extendicare operates a network of 99 long-term care homes, providing approximately 11.2 million hours of home health care services annually [5] - The company employs around 26,500 qualified team members dedicated to delivering high-quality care [5]

Core Points - Extendicare Inc. held its annual and special meeting of shareholders on May 27, 2025, where various matters were voted on [1] - A total of 47,282,730 common shares were represented at the meeting, accounting for 56.41% of the outstanding shares [2] Group 1: Election of Directors - Nine nominees were elected as directors to serve until the next annual meeting [3] - The voting results showed high approval rates for the nominees, with votes for ranging from 94.08% to 99.74% [4] Group 2: Appointment of Auditors - KPMG LLP was appointed as the auditors of the Company until the next annual meeting, with 87.18% of votes in favor [5][6] Group 3: Long Term Incentive Plan - The resolution to approve unallocated entitlements under Extendicare's Long Term Incentive Plan was passed with 97.04% approval [7][8] Group 4: Executive Compensation - A non-binding advisory resolution regarding the Company's approach to executive compensation was approved, receiving 94.48% of votes in favor [9][10][11] Company Overview - Extendicare is a leading provider of care and services for seniors in Canada, operating 122 long-term care homes and delivering approximately 11.2 million hours of home health care services annually [12]

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 08, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended March 31, 2025. All amounts are in United States dollars unless otherwise specified. Nova Leap Q1 2025 Financial Results Financial results for the first quarter ended March 31, 2025 ...

First Quarter 2025 Earnings Presentation May 2, 2025 1 Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-lookin ...

Company Performance - Amedisys reported quarterly earnings of $1.25 per share, exceeding the Zacks Consensus Estimate of $1.13 per share, and up from $1.03 per share a year ago, representing an earnings surprise of 10.62% [1] - The company posted revenues of $594.78 million for the quarter ended March 2025, which aligns with the Zacks Consensus Estimate and shows an increase from $571.41 million year-over-year [2] - Over the last four quarters, Amedisys has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Future Outlook - The sustainability of Amedisys's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $1.43 on revenues of $616.25 million, and for the current fiscal year, it is $4.78 on revenues of $2.45 billion [7] - The estimate revisions trend for Amedisys is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Amedisys belongs, is currently ranked in the top 8% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Amedisys's performance [5]